Calprotectin is a complex of two anionic proteins found in abundance in the cytosol of neutrophils, certain macrophages, and oral epithelial keratinocytes. Bacteria of the genus Capnocytophaga are pathogens of periodontal origin which can cause systemic infection in neutropenic subjects. Recently, it has been observed that Capnocytophaga may be internalized by neutrophils within the cytosol rather than within a membrane-delimited phagosome. The purpose of this study was to test the in vitro antibacterial effect of the cytosolic complex, calprotectin, against Capnocytophaga sputigena. Calprotectin was purified from the cytosol of human neutrophils by gel filtration and anion exchange FPLC, and it exerted potent in vitro antimicrobial effects against C. sputigena. Net bacteriostatic activity was exerted up to 18 h, after which bactericidal effects were observed. Both net bacteriostatic and bactericidal activity occurred at concentrations above 20 μg/mL and exhibited identical dose-response characteristics. Particle counts increased in the presence of calprotectin, despite net bacteriostasis as assessed by changes in colony-forming units (CFU). Dose-response characteristics and direct particle counts suggested that net bacteriostatic effects were the result of balanced cell division and death, rather than suspension of cell division. We conclude that calprotectin can be a significant contributor to host defense against infection by Capnocytophaga.
Get full access to this article
View all access options for this article.
References
1.
Andersson KB, Sletten K., Berntzen HB, Dale I., Brandtzaeg P., Jellum E., et al. (1988). The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol28:241-245.
2.
Baker PJ, Wilson ME (1988). Effect of clindamycin on neutrophil killingof Gram-negative periodontal bacteria. Antimicrob Agents Chemother32:1521-1527.
3.
Berntzen HB, Fagerhol MK (1988). L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest48:647-652.
4.
Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding . Anal Biochem7:248-254.
5.
Brandtzaeg P., Dale I., Fagerhol MK (1987a). Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. I. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. Am J Clin Pathol87:681-699.
6.
Brandtzaeg P., Dale I., Fagerhol MK (1987b). Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. II. Normal and aberrant occurrence in various epithelia. Am J Clin Pathol87:700-707.
7.
Brandtzaeg P., Jones DB, Flavell DJ, Fagerhol MK (1988). Mac 387 antibody and detection of formalin resistant myelomonocytic L1 antigen. J Clin Pathol41:963-970.
8.
Brüggen J., Tarcsay L., Cerletti J., Odink K., Rutishauser M., Hollander G., et al. (1988). The molecular nature of the cystic fibrosis antigen. Nature (London)331:570.
9.
Challacombe SJ, Wilton Jma (1984). A study of antibodies and opsonic activity in human crevicular fluid in relation to periodontal disease. J Periodont Res19:604-608.
10.
Dale I., Fagerhol MK, Naesgaard I. (1983). Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem134:1-6.
11.
Dorin JR, Novak M., Hill RE, Brock Djh, Secher DS, Van Heyningen V. (1987). A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene. Nature (London)326:614-617.
12.
Edgeworth J., Gorman M., Bennett R., Freemont P., Hogg N. ( 1991). Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem266:7706-7713.
13.
Flavell DJ, Jones DB, Wright DH (1987). Identification of tissue histiocytes on paraffin sections by a new monoclonal antibody. J Histochem Cytochem35:1217-1226.
14.
Forlenza SW, Newman MG, Lipsey AI, Seigel SE, Blachman U. (1980). Capnocytophaga sepsis: a newly recognized clinical entity in granulocytopenic patients. Lanceti:567-568.
Gandola C., Butler T., Badger S., Cheng E., Beard S. (1980). Septicemia caused by Capnocytophaga in a granulocytopenic patient with glossitis. Arch Intern Med140:851-852.
HoggN., Allen C., Edgeworth J. (1989). Monoclonal antibody 5.5 reacts with p8,14, a myeloid molecule associated with vascular endothelium. Eur J Biochem19:1053-1061.
19.
Kligman D., Hilt DC ( 1988). The S100 protein family. Trends Biochem Sci13:437-443.
20.
Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London)277:680-685.
21.
Lagasse E., Clerc RG (1988). Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation . Mol Cell Biol8:2402-2410.
22.
LeGendre N., Matsudaira P. (1989). Purification of proteins and peptides by SDS-PAGE . In: Matsudaira P, editor. A practical guide to protein and peptide purification for microsequencing . San Diego (CA): Academic Press, Inc., 49-69.
23.
Miyasaki KT, Bodeau AL (1991). In vitro killing of oral Capnocytophaga by granule fractions of human neutrophils is associated with cathepsin G activity. J Clin Invest87:1585-1593.
24.
Miyasaki KT, Bodeau AL, Ganz T., Selsted ME, Lehrer RI (1990). Sensitivity of oral, Gram-negative, facultative bacteria to the bactericidal activity of human neutrophil defensins. Infect Immun58:3934-3940.
25.
Murao S., Collart FR, Huberman E. (1989). A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem264:8356-8360.
26.
Murao S., Collart FR, Huberman E. (1990). A protein complex expressed during terminal differentiation of monomyelocytic cells is an inhibitor of cell growth. Cell Growth & Differentiation1 :447-457.
27.
Odink K., Cerletti N., Brüggen J., Clerc RG, Tarcsay L., Zwadlo G., et al. (1987). Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature (London)330:80-82.
28.
Shenkein HA, Genco RJ (1977). Gingival fluid and serum in periodontal diseases. I. Quantitative study of immunoglobulins, complement, and other plasma proteins . J Periodontol48 :772-777.
29.
Shurin SB, Socransky SS, Sweeney E., Stossal TP (1979). A neutrophil disorder induced by Capnocytophaga, a dental microorganism. N Eng J Med301:849-854.
30.
Sohnle PG, Collins-Lech C., Wiessner JH (1990). Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis163:187-192.
31.
Sohnle PG, Collins-Lech C., Wiessner JH (1991). The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis164:136-142.
32.
SteinbakkM, Naess-Andersen C-F, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK (1990). Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336:763-765. Suffin SC, Muck KB, YoungJC, Lewin K, Porter DD (1979). Improvement of the glucose oxidase immunoenzyme technique. Use of a tetrazolium whose formazan is stable without heavy metal chelation. Am J Clin Pathol 71:492-496.
33.
Teigelkamp S., Bhardwaj RS, Roth J., Meinardus-Hager G., Karas M., Sorg C. ( 1991). Calcium-dependent complex assembly of the myeloic differentiation proteins MRP-8 and MRP-14. J Biol Chem266:13462-13467.
34.
Thompson HL, Wilton Jma (1991). Effects of anaerobiosis and aerobiosis on the interactions of human polymorphonuclear leukocytes with the dental plaque bacteria Streptococcus mutans, Capnocytophaga ochracea, and Bacteroides gingivalis . Infect Immun59:932-940.
35.
Van Heyningen V, Dorin J (1990). Possible role for two calcium-binding proteins of the S-100 family, co-expressed in granulocytes and certain epithelia. Adv Exp Med Biol 269:139-143. Wilkinson MM, Bussittil A, Hayward C, Brock DJH, Dorin JR, Van Heyningen V (1988). Expression pattern of two related cystic fibrosis associated calcium-binding proteins in normal and abnormal tissues. J Cell Sci 91:221-230.
36.
Wilson ME, Jonak-Urbanczyk JT, Bronson PM, Dudas KC, Apicella MA, Genco RJ (1987). Capnocytophaga species: increased resistance of clinical isolates to serum bactericidal action. J Infect Dis156:99-106.
